E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma

Vivien H C Bramwell, A. Brugarolas, H. T. Mouridsen, Françoise Cheix, R. De Jager, A. T. Van Oosterom, C. P. Vendrik, H. M. Pinedo, R. Sylvester, Marlene De Pauw

Research output: Contribution to journalArticlepeer-review

23 Scopus citations


Cis-diamminodichloroplatinum (II) (cis-DDP), 100 mg/m2 every 3 weeks was administered to 24 patients with advanced soft tissue sarcoma. All patients had received extensive prior chemotherapy and had measurable progressive disease and normal renal function on entry to the study. There were no objective responses in the 17 patients receiving an adequate trial of therapy. Nausea and vomiting were universal. Renal impairment was moderate in 2 patients and mild in 4. Serial audiometry detected hearing loss at high frequencies in 3 patients.

Original languageEnglish (US)
Pages (from-to)1511-1513
Number of pages3
JournalEuropean Journal of Cancer (1965)
Issue number12
StatePublished - 1979
Externally publishedYes

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'E.O.R.T.C. phase II study of cisplatin in cyvadic-resistant soft tissue sarcoma'. Together they form a unique fingerprint.

Cite this